## **Amendments to the Claims** C.

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (currently amended) An antisense oligonucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of at least 15 successive nucleotides in the nucleotide sequence consisting of nucleotides 6-44 of SEQ ID NO: 1.
- 2. (currently amended) An antisense oligonucleotide comprising a nucleotide sequence which specifically hybridizes to a nucleotide sequence consisting of at least 15 successive nucleotides in the nucleotide sequence consisting of nucleotides 6-44 of SEQ ID NO: 1.
- 3. (previously presented) The oligonucleotide according to claim 1 wherein at least one internucleotide bond is a phosphorothioate bond.
- 4. (currently amended) A pharmaceutical composition comprising the oligonucleotide according to claim 1, and a pharmaceutically acceptable carrier or diluent.
- 5. (previously presented) An anti-HIV agent comprising the oligonucleotide according to claim 1.

6. *(currently amended)* A pharmaceutical composition for treating or preventing HIV, comprising the oligonucleotide according to claim 1, and a pharmaceutically or veterinarily acceptable carrier or diluent.

## 7-8. (cancelled)

- 9. *(previously presented)* The oligonucleotide according to claim 2, wherein at least one internucleotide bond is a phosphorothioate bond.
- 10. *(currently amended)* A pharmaceutical composition comprising the oligonucleotide according to claim 2, and a pharmaceutically acceptable carrier or diluent.
- 11. *(currently amended)* A pharmaceutical composition comprising the oligonucleotide according to claim 3, and a pharmaceutically acceptable carrier or diluent.
- 12. *(previously presented)* An anti-HIV agent comprising the oligonucleotide according to claim 2.
- 13. *(previously presented)* An anti-HIV agent comprising the oligonucleotide according to claim 3.

14. *(currently amended)* A pharmaceutical composition for treating or preventing HIV, comprising the oligonucleotide according to claim 2, and a pharmaceutically acceptable carrier or diluent.

15. *(currently amended)* A pharmaceutical composition for treating or preventing HIV, comprising the oligonucleotide according to claim 3, and a pharmaceutically acceptable carrier or diluent.

16-17. (canceled)

\* \* \* \* \*